Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to ...

Ozempic Knockoffs Survive Crackdown Thanks to Loophole Providers of compounded obesity drugs are finding-for now-a new way into the booming market by tweaking formulations. International Paper Is ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market. It hasn’t exactly worked out that way.

May 16 (Reuters) - Ozempic-maker Novo Nordisk (NOVOb.CO ... losing its first-mover advantage in the competitive obesity drug market to American rival Eli Lilly (LLY.N), opens new tab.